Back to Search
Start Over
Characterization of a new dual-targeting fully human antibody with potent antitumor activity against nasopharyngeal carcinoma
- Source :
- Biological chemistry. 396(8)
- Publication Year :
- 2014
-
Abstract
- Despite the effectiveness of the anti-EGFR chimeric antibody (mAb), cetuximab, in treating nasopharyngeal carcinoma (NPC), its efficacy remains variable and often modest. In this study, a full human dual targeted anti-EGFR/HER3 antibody, CA1182, was generated from phage display library. CA1182 was as effective as cetuximab or trastuzumab in inhabiting phosphorylation of EGFR or HER2, but it exhibited as much more potent than cetuximab or trastuzumab. Moreover, our studies showed that CA1182 was significantly more effective than cetuximab in prolonging the survival of severe combined immune deficient mice bearing human NPC, suggesting that it might be a promising therapeutic agent for NPC.
- Subjects :
- Phage display
medicine.drug_class
Clinical Biochemistry
Nasopharyngeal neoplasm
Cetuximab
Antineoplastic Agents
Pharmacology
Monoclonal antibody
Biochemistry
Mice
Trastuzumab
Cell Line, Tumor
medicine
Carcinoma
Animals
Humans
skin and connective tissue diseases
neoplasms
Molecular Biology
Nasopharyngeal Carcinoma
biology
business.industry
Antibodies, Monoclonal
Nasopharyngeal Neoplasms
medicine.disease
Xenograft Model Antitumor Assays
digestive system diseases
ErbB Receptors
Nasopharyngeal carcinoma
biology.protein
Antibody
business
medicine.drug
Subjects
Details
- ISSN :
- 14374315
- Volume :
- 396
- Issue :
- 8
- Database :
- OpenAIRE
- Journal :
- Biological chemistry
- Accession number :
- edsair.doi.dedup.....c9594cd5840aafe76744d371615ef5a1